Narsoplimab(一种甘露聚糖结合凝集素相关丝氨酸蛋白酶-2抑制剂)治疗成人造血干细胞移植相关血栓性微血管病
这项单臂开放标签关键性试验纳入28例成人HSCT-TMA患者,每周静脉给予Narsoplimab 4-8周。FAS人群应答率61%,器官功能改善率74%,移植后100天生存率FAS人群68%、应答者94%,中位总生存274天。Narsoplimab耐受良好,不良事件为该人群典型表现,无令人担忧的安全性信号。
要点
- Narsoplimab在成人HSCT-TMA中应答率61%,器官功能改善率74%。
- FAS人群100天生存率68%,应答者94%,中位总生存274天。
- Narsoplimab耐受良好,不良事件为该人群典型表现,无安全性信号。
核心结论
- Narsoplimab治疗安全,显著改善实验室TMA标志物,并产生临床应答和有利的总生存。
研究设计与样本
- 单臂开放标签关键性试验(NCT02222545),患者每周静脉给予Narsoplimab 4-8周,至少接受一剂者纳入全分析集(FAS;N=28)。
- 主要终点为应答率,要求两类临床改善:(1)实验室TMA标志物(血小板计数和乳酸脱氢酶均改善)和(2)器官功能或脱离输血。
主要发现
- FAS人群应答率为61%。
- 按基线特征、HSCT特征和HSCT并发症定义的所有患者亚组中观察到相似应答。
- FAS人群器官功能改善发生于74%的患者。
- HSCT-TMA诊断后100天生存率FAS人群为68%,应答者为94%;FAS人群中位总生存为274天。
- Narsoplimab耐受良好,不良事件为该人群典型表现,无令人担忧的安全性信号。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication with significant mortality and no approved therapy. HSCT-TMA results from endothelial injury, which activates the lectin pathway of complement. Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA. METHODS: In this single-arm open-label pivotal trial (NCT02222545), patients received intravenous narsoplimab once weekly for 4-8 weeks. The primary end point (response rate) required clinical improvement in two categories: (1) laboratory TMA markers (both platelet count and lactate dehydrogenase) and (2) organ function or freedom from transfusion. Patients receiving at least one dose (full analysis set [FAS]; N = 28) were analyzed. RESULTS: The response rate was 61% in the FAS population. Similar responses were observed across all patient subgroups defined by baseline features, HSCT characteristics, and HSCT complications. Improvement in organ function occurred in 74% of patients in the FAS population. One-hundred-day survival after HSCT-TMA diagnosis was 68% and 94% in FAS population and responders, respectively, whereas median overall survival was 274 days in the FAS population. Narsoplimab was well tolerated, and adverse events were typical of this population, with no apparent safety signal of concern. CONCLUSION: In this study, narsoplimab treatment was safe, significantly improved laboratory TMA markers, and resulted in clinical response and favorable overall survival.
引用
- Khaled SK, Claes K, Goh YT, et al. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022. PMID: 35439028. doi:10.1200/JCO.21.02389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。